Replies to post #205568 on Cytodyn Inc (CYDY)

[ClosetInvestor]

“My initial thoughts:

1, Subgroup or not, why didn't these 3 lawyers acknowledge the amazing success of LL in reducing mortality after 7 and 14 days?”

News flash: there wasn’t an amazing success with the subgroups. A sub-group analysis from a failed trial is flawed from the onset. Per the FDA, there were sub-groups who favored placebo and others who favored leronlimab and none were statically significant.

“Here, the data from CD12 illustrated imbalances in mortality among subgroups, some favoring leronlimab and some favoring placebo. None of these analyses met statistical significance when using established and reliable analytical methods that correct for multiple comparisons.”

[HyGro]

LL FAILED the CD12 trial -- missed ALL endpoints. No amount of post-hoc data dredging will change that. In fact even the 62 critical patients with the "82%" was NOT statistically significant when using the appropriate statistical analysis -- not NPs manipulations. The trial was recruited properly -- CD12 average 58 years old for BOTH the treatment and placebo arm. The critical subgroup was NOT designed for an analysis or they would have designed for the analysis in the protocol, stratified the sample and had sufficient size for an viable analysis -- THEY DIDN'T so it has no validity as a trial analysis.